Table 1

Summary data for subjects from whom C. difficile was isolated and classification of isolates regarding ribotype and the presence of a pathogenicity locus

SubjectSexAge (yr)RibotypeStratificationaAntibiotic usage within 4 weeks prior to samplingtcdA/tcdB
EM011F86027DNo antibiotic usage recorded+/+
EM012F85002DUnknown+/+
EM045M67072DNo antibiotic usage recorded+/+
EM069M83072RNo antibiotic usage recorded+/+
EM112F84027LSAmoxicillin, tazocin, flagyl, ciprofloxacin+/+
EM113M75072RPenicillin, moxifloxacin+/+
EM124M79072LSCiproxin, augmentin+/+
EM126M75072LSNo antibiotic usage recorded+/+
EM136M73014LSNo antibiotic usage recorded+/+
EM139F69072LSNo antibiotic usage recorded+/+
EM140F78072LSNo antibiotic usage recorded+/+
EM146F88308LSNo antibiotic usage recorded+/+
EM148M71072RNo antibiotic usage recorded+/+
EM149F82010CFlucloxacillin–/–
EM152F87050RNo antibiotic usage recorded+/+
EM156M74220LSNo antibiotic usage recorded+/+
EM186F87308LSTrimethoprim, augmentin+/+
EM188F96018LSAugmentin+/+
EM218F90072LSCephradine, co-amoxiclav+/+
EM243F81072LSNo antibiotic usage recorded+/+
EM255F91072LSAugmentin+/+
EM304F77027RKlacid, clindamycin, flucoxacillin, penicillin, metronidazole, trimethoprim, ciprofloxacin, vancomycin, co-amoxiclav, tazocin+/+
EM306F87027RVancomycin, flagyl+/+
EM308M82078RNo antibiotics+/+
EM321F84026RNo antibiotics–/–
EM324F81216RCo-amoxiclav+/+
EM334M83216RNo antibiotics+/+
EM336F70216CClarithromycin, co-amoxiclav+/+
  • a D, subjects in hospital as day patients; R, subjects in rehabilitation, i.e., less than 6 weeks as an in-patient; LS, long stay,i.e., subjects more than 6 weeks as an in-patient; C, community-dwelling subjects.